Alternate-day fasting exacerbates doxorubicin cardiotoxicity in cancer chemotherapy

Doxorubicin (Dox) is a highly potent chemotherapy drug. Despite its efficacy, Dox's clinical application is limited due to its association with significant complications, namely cardiotoxicity and the risk of heart failure. Recent intriguing findings by Ozcan et al. indicate that alternate-day fasting (ADF) significantly exacerbates the cardiotoxicity of Dox.

Automated summary

Doxorubicin (Dox) is an effective chemotherapy drug, but its clinical use is limited due to cardiotoxicity and the risk of heart failure. Recent research by Ozcan et al. suggests that alternate-day fasting (ADF) can significantly worsen the cardiotoxicity of Dox.